ATE511850T1 - Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin - Google Patents

Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin

Info

Publication number
ATE511850T1
ATE511850T1 AT08004714T AT08004714T ATE511850T1 AT E511850 T1 ATE511850 T1 AT E511850T1 AT 08004714 T AT08004714 T AT 08004714T AT 08004714 T AT08004714 T AT 08004714T AT E511850 T1 ATE511850 T1 AT E511850T1
Authority
AT
Austria
Prior art keywords
integrin
antibodies
beta
alpha
treatment
Prior art date
Application number
AT08004714T
Other languages
English (en)
Inventor
Xiaozhu Huang
Dean Sheppard
Robert Pytela
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE511850T1 publication Critical patent/ATE511850T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT08004714T 1997-08-08 1998-08-07 Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin ATE511850T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5506097P 1997-08-08 1997-08-08

Publications (1)

Publication Number Publication Date
ATE511850T1 true ATE511850T1 (de) 2011-06-15

Family

ID=21995323

Family Applications (3)

Application Number Title Priority Date Filing Date
AT08004714T ATE511850T1 (de) 1997-08-08 1998-08-07 Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin
AT04022921T ATE410179T1 (de) 1997-08-08 1998-08-07 Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern
AT98939278T ATE286742T1 (de) 1997-08-08 1998-08-07 Behandlung von nierenfibrose durch antikörper gegen integrin alpha-v-beta 6

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT04022921T ATE410179T1 (de) 1997-08-08 1998-08-07 Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern
AT98939278T ATE286742T1 (de) 1997-08-08 1998-08-07 Behandlung von nierenfibrose durch antikörper gegen integrin alpha-v-beta 6

Country Status (23)

Country Link
US (5) US20020004482A1 (de)
EP (3) EP0996460B1 (de)
JP (2) JP2001513333A (de)
KR (1) KR100586202B1 (de)
CN (1) CN1267224A (de)
AT (3) ATE511850T1 (de)
AU (1) AU739283B2 (de)
BR (1) BR9814040A (de)
CA (1) CA2297736A1 (de)
CY (2) CY1110462T1 (de)
CZ (1) CZ299768B6 (de)
DE (2) DE69828614T2 (de)
DK (2) DK1930022T3 (de)
EE (1) EE04752B1 (de)
ES (3) ES2311131T3 (de)
HU (1) HU228900B1 (de)
IL (2) IL134288A0 (de)
NZ (2) NZ515955A (de)
PL (2) PL201716B1 (de)
PT (3) PT1504764E (de)
RU (1) RU2221589C2 (de)
TR (2) TR200202323T2 (de)
WO (1) WO1999007405A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
EP0996460B1 (de) * 1997-08-08 2005-01-12 The Regents of the University of California Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6
PL198975B1 (pl) * 1999-04-22 2008-08-29 Biogen Idec Inc Zastosowanie kompozycji zawierającej homolog przeciwciała, który jest antagonistą interakcji między integryną niosącą podjednostkę alfa 4 a jej ligandem
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
ES2312569T3 (es) * 2001-04-30 2009-03-01 Eli Lilly And Company Anticuerpos humanizados.
CN1646160A (zh) * 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
EP1492870A4 (de) * 2002-04-12 2005-08-03 Raven Biotechnologies Inc An integrin-alpha-v-beta-6 bindende antikörper sowie verfahren zur verwendung davon
PL1734996T3 (pl) * 2004-04-02 2013-09-30 Univ California Sposoby i kompozycje do leczenia i profilaktyki choroby związanej z integryną alfa v beta 5
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
SG173364A1 (en) 2006-07-10 2011-08-29 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
KR20090039739A (ko) * 2006-08-03 2009-04-22 아스트라제네카 아베 αＶβ６에 대해 작용하는 항체 및 그의 용도
AU2007354317A1 (en) * 2006-10-19 2008-12-04 Biogen Idec Ma Inc. Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
KR101046317B1 (ko) * 2008-07-04 2011-07-05 이종대 조력발전 방법 및 그 장치
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
CA2767409C (en) 2009-07-24 2018-10-30 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
KR20120054077A (ko) * 2009-08-21 2012-05-29 길리아드 바이오로직스, 인크. 폐 섬유증 장애의 치료를 위한 방법 및 조성물
RU2012110585A (ru) 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Каталичические домены лизилоксидазы и loxl2
US8680246B2 (en) * 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
US9493566B2 (en) 2012-02-17 2016-11-15 Seattle Genetics, Inc. Antibodies to integrin AVB6 and use of same to treat cancer
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
EP2784511A1 (de) 2013-03-27 2014-10-01 Universität Zürich Integrin-alpha-v-beta 6 zur Diagnose/Prognose von Kolorektalkarzinomen
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
HK1254295A1 (zh) * 2015-11-23 2019-07-19 默克专利股份有限公司 用於治疗纤维化和/或纤维化病症的抗-αＶ整合素抗体
AU2018322475A1 (en) 2017-08-22 2020-03-05 Biogen Ma Inc. Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
IL293195A (en) 2019-12-05 2022-07-01 Seagen Inc Anti-avb6 antibodies and antibody-drug conjugates
CN115989235A (zh) * 2020-05-07 2023-04-18 普利安特治疗公司 使用氨基酸化合物治疗呼吸系统疾病的方法
CN120960406A (zh) * 2024-05-16 2025-11-18 浙江大学 靶向整合素αVβ6的CAR-免疫细胞在预防和/或治疗纤维化疾病中的应用
WO2026012032A1 (en) * 2024-07-10 2026-01-15 Wuxi Biologics (Shanghai) Co., Ltd. Antibodies against integrin and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
FI912858A0 (fi) 1988-12-20 1991-06-13 Jolla Cancer Res Found Polypeptidpolymerkonjugat aktiva vid botande av saor.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
DE69531187T2 (de) * 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
EP0996460B1 (de) * 1997-08-08 2005-01-12 The Regents of the University of California Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6

Also Published As

Publication number Publication date
DE69840113D1 (de) 2008-11-20
TR200202323T2 (tr) 2002-12-23
CY1111792T1 (el) 2015-10-07
EP1504764B1 (de) 2008-10-08
AU739283B2 (en) 2001-10-11
EP0996460A1 (de) 2000-05-03
HU228900B1 (en) 2013-06-28
KR100586202B1 (ko) 2006-06-07
IL134288A (en) 2008-07-08
DK1930022T3 (da) 2011-07-25
EE200000068A (et) 2000-10-16
CA2297736A1 (en) 1999-02-18
NZ502546A (en) 2002-02-01
EP1930022A1 (de) 2008-06-11
WO1999007405A1 (en) 1999-02-18
HUP0003547A3 (en) 2002-05-28
US20020004482A1 (en) 2002-01-10
PT996460E (pt) 2005-04-29
ES2364703T3 (es) 2011-09-12
PL199014B1 (pl) 2008-08-29
KR20010022740A (ko) 2001-03-26
US6316601B1 (en) 2001-11-13
RU2221589C2 (ru) 2004-01-20
HUP0003547A2 (hu) 2001-02-28
PL341029A1 (en) 2001-03-26
CZ2000413A3 (cs) 2000-11-15
TR200000374T2 (tr) 2000-09-21
BR9814040A (pt) 2000-10-03
ATE286742T1 (de) 2005-01-15
CY1110462T1 (el) 2015-04-29
US7544358B2 (en) 2009-06-09
ATE410179T1 (de) 2008-10-15
CN1267224A (zh) 2000-09-20
DE69828614D1 (de) 2005-02-17
CZ299768B6 (cs) 2008-11-19
EP1504764A1 (de) 2005-02-09
US6692741B2 (en) 2004-02-17
EE04752B1 (et) 2006-12-15
EP0996460B1 (de) 2005-01-12
US20040208878A1 (en) 2004-10-21
EP0996460A4 (de) 2001-03-07
JP2009001587A (ja) 2009-01-08
JP2001513333A (ja) 2001-09-04
US20070148173A1 (en) 2007-06-28
NZ515955A (en) 2003-04-29
ES2235350T3 (es) 2005-07-01
EP1930022B1 (de) 2011-06-08
IL134288A0 (en) 2001-04-30
DE69828614T2 (de) 2006-02-09
US20010056076A1 (en) 2001-12-27
ES2311131T3 (es) 2009-02-01
PT1930022E (pt) 2011-08-01
US7150871B2 (en) 2006-12-19
PT1504764E (pt) 2009-01-14
PL201716B1 (pl) 2009-05-29
DK1504764T3 (da) 2008-11-17
AU8774398A (en) 1999-03-01

Similar Documents

Publication Publication Date Title
DE69828614D1 (de) Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6
FI961083L (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
ATE330630T1 (de) Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose
CY2010011I2 (el) Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
DE69515891T8 (de) Verbundstoff und saugfähiges Kleidungsstück mit diesem Verbundstoff
IL117993A0 (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
DE122007000002I2 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes.
CY2013010I1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
DE60043957D1 (de) Verfahren zur Behandlung von Entzündungen
DE68918497D1 (de) Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika.
DE69532208D1 (de) Stenteinführungsvorrichtung mit arzneimittelspender und herstellungsverfahren
FI972703L (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
NO994165D0 (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
DE60237447D1 (de) Verwendung von polyklonalen anti-hiv ziegenseren als therapeutisches mittel
FI973484A0 (fi) Menetelmä immuunivasteen stimuloimiseksi
DE60027413D1 (de) Herstellung von superabsorbierenden materialien in umgekehrten emulsionen mit grosser innerer phase
DE69129582D1 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
ID21895A (id) Antibodi yang mengikat kepada grup laminin yang mengikat nidogen, pembuatannya dan penggunaannya
EP1013642A3 (de) Chelatoren sowie deren Tricarbonyl-Komplexe mit Technetium und Rhenium
IS4387A (is) Nýtt skömmtunarform hýdroxókóbalamíns og notkun þess við sýaníðeitrunum
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
DE69118702D1 (de) Neue verwendung eines monoklonalen antikörpers
RU99123884A (ru) Способ лечения параноидной шизофрении
IT1238998B (it) Procedimento per la parzializzazione dei tempi ciclo nei dispositivi programmatori e dispositivi relativi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1930022

Country of ref document: EP